miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling

Jessica Teitel & Analisa DiFeo et al. · 2020-06-26

Abstract

Genomic instability (GI) predisposes cells to malignant transformation, however the molecular mechanisms that allow for the propagation of cells with a high degree of genomic instability remain unclear. Here we report that miR-181a is able to transform fallopian tube secretory epithelial cells through the inhibition of RB1 and stimulator-of-interferon-genes (STING) to propagate cells with a high degree of GI. MiR-181a targeting of RB1 leads to profound nuclear defects and GI generating aberrant cytoplasmic DNA, however simultaneous miR-181a mediated inhibition of STING allows cells to bypass interferon mediated cell death. We also found that high miR-181a is associated with decreased IFNγ response and lymphocyte infiltration in patient tumors. DNA oncoviruses are the only known inhibitors of STING that allow for cellular transformation, thus, our findings are the first to identify a miRNA that can downregulate STING expression to suppress activation of intrinsic interferon signaling. This study introduces miR-181a as a putative biomarker and identifies the miR-181a-STING axis as a promising target for therapeutic exploitation.

Funding
Project 1Training Program in Translational ResearchDevelopmental TherapeuticsPre-doctoral Training Program in Molecular TherapeuticsExamining the role of the miR-181a:Wnt/B-catenin axis in ovarian cancerUniversity of Michigan Rogel Cancer Center Support Grant 2023-2028Project 1Pre-doctoral Training Program in Molecular TherapeuticsExamining the role of the miR-181a:Wnt/B-catenin axis in ovarian cancerU.S. Department of Health & Human Services | NIH | National Cancer Institute FundingU.S. Department of Defense Grant OC150553

NCI NIH HHS

P50 CA159981

NIGMS NIH HHS

T32 GM113900

NCI NIH HHS

P30 CA043703

NIGMS NIH HHS

T32 GM008803

NCI NIH HHS

R01 CA197780

NCI NIH HHS

P30 CA046592

U.S. Department of Health & Human Services | NIH | National Cancer Institute

P50CA159981

U.S. Department of Health & Human Services | NIH | National Cancer Institute

T32GM008803-11A1

U.S. Department of Health & Human Services | NIH | National Cancer Institute

R01CA197780